NasdaqCM - Delayed Quote • USD
Biomerica, Inc. (BMRA)
At close: April 18 at 4:00 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | 1 | -- |
| Avg. Estimate | -- | -- | 26.59M | -- |
| Low Estimate | -- | -- | 26.59M | -- |
| High Estimate | -- | -- | 26.59M | -- |
| Year Ago Sales | -- | -- | 5.34M | 26.59M |
| Sales Growth (year/est) | -- | -- | 398.00% | -- |
Earnings History
| CURRENCY IN USD | ||||
|---|---|---|---|---|
| EPS Est. | -- | -- | -- | -- |
| EPS Actual | -- | -- | -- | -- |
| Difference | -- | -- | -- | -- |
| Surprise % | -- | -- | -- | -- |
EPS Trend
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0.39 | 0 |
| 30 Days Ago | 0 | 0 | 0.39 | 0 |
| 60 Days Ago | 0 | 0 | 0.39 | 0 |
| 90 Days Ago | 0 | 0 | 0.39 | 0 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (May 2024) | Next Qtr. (Aug 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | BMRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -- | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | -- | -- | -- | 4.50% |
| Next Year | -- | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | 24.07% | -- | -- | -- |
Research Analysis
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Upgrades & Downgrades
| Maintains | Aegis Capital: Buy | 10/19/2020 |
| Maintains | Aegis Capital: Buy | 9/4/2020 |
| Initiated | Aegis Capital: Buy | 8/21/2020 |
| Maintains | B. Riley Securities: Buy to Buy | 12/17/2018 |
Related Tickers
THMO ThermoGenesis Holdings, Inc.
0.6500
+4.18%
RMSL REMSleep Holdings, Inc.
0.0099
+0.41%
HSDT Helius Medical Technologies, Inc.
5.11
-0.97%
INBS Intelligent Bio Solutions Inc.
2.8000
+5.26%
APYX Apyx Medical Corporation
1.3800
+4.55%
TIVC Tivic Health Systems, Inc.
1.1570
+4.23%
BBLG Bone Biologics Corporation
1.7950
+8.13%
HSCS Heart Test Laboratories, Inc.
0.1085
+7.43%
AIMD Ainos, Inc.
1.0300
-0.96%
NAOV NanoVibronix, Inc.
0.7500
-3.24%